Risk of Colorectal Cancer Linked to Composition of the Gut Microbiome
|
By LabMedica International staff writers Posted on 17 Dec 2013 |
The composition of the community of bacteria living in the digestive tract has been linked to the risk of developing colorectal cancer (CRC).
Colorectal cancer is diagnosed in about 143,000 Americans annually with nearly 51,000 fatalities, making it second only to lung cancer in the number of deaths caused each year. However, it is not well understood why colorectal cancer develops.
Investigators at the New York University School of Medicine (NY, USA) tested the hypothesis that an altered community of gut microbes was associated with risk of developing CRC. To this end, they compared the DNA composition of intestinal microbes in the stool samples of 47 CRC patients and 94 healthy volunteers.
16S rRNA genes in fecal bacterial DNA were amplified by universal primers, sequenced by Roche (Basel, Switzerland) 454 FLX technology, and aligned for taxonomic classification to microbial genomes using the QIIME protocol.
QIIME, which stands for Quantitative Insights into Microbial Ecology, is an open source software package for comparison and analysis of microbial communities, primarily based on high-throughput amplicon sequencing data generated on a variety of platforms, but also supporting analysis of other types of data. QIIME chaperones users from their raw sequencing output through initial analyses such as OTU (operational taxonomic unit) picking, taxonomic assignment, and construction of phylogenetic trees from representative sequences of OTUs, and through downstream statistical analysis, visualization, and production of publication-quality graphics. QIIME has been applied to studies based on billions of sequences from thousands of samples.
Taxonomic differences identified in this study were confirmed by quantitative polymerase chain reaction (qPCR) and adjusted for false discovery rate. Data from 794,217 16S rRNA gene sequences revealed that CRC case subjects had decreased overall microbial community diversity. In taxonomy-based analyses, lower relative abundance of Clostridia and increased carriage of Fusobacterium and Porphyromonas were found in case subjects compared with control subjects. Clostridia include some bacterial family members that ferment dietary fiber to butyrate, which is a major colonic metabolite that may inhibit inflammation and carcinogenesis in the colon, while Fusobacterium and Porphyromonas are related to inflammation in the mouth and gastrointestinal track.
"Our findings are important because identification of these microbes may open the door for colorectal cancer prevention and treatment," said first author Dr. Jiyoung Ahn, assistant professor of population health at the New York University School of Medicine. "Our next step is to study how diet and lifestyle factors modulate these gut bacteria associated with colorectal cancer. This may lead to ways to prevent this disease."
The paper was published in the December 6, 2013, online edition of the Journal of the [US] National Cancer Institute.
Related Links:
New York University School of Medicine
Roche
QIIME
Colorectal cancer is diagnosed in about 143,000 Americans annually with nearly 51,000 fatalities, making it second only to lung cancer in the number of deaths caused each year. However, it is not well understood why colorectal cancer develops.
Investigators at the New York University School of Medicine (NY, USA) tested the hypothesis that an altered community of gut microbes was associated with risk of developing CRC. To this end, they compared the DNA composition of intestinal microbes in the stool samples of 47 CRC patients and 94 healthy volunteers.
16S rRNA genes in fecal bacterial DNA were amplified by universal primers, sequenced by Roche (Basel, Switzerland) 454 FLX technology, and aligned for taxonomic classification to microbial genomes using the QIIME protocol.
QIIME, which stands for Quantitative Insights into Microbial Ecology, is an open source software package for comparison and analysis of microbial communities, primarily based on high-throughput amplicon sequencing data generated on a variety of platforms, but also supporting analysis of other types of data. QIIME chaperones users from their raw sequencing output through initial analyses such as OTU (operational taxonomic unit) picking, taxonomic assignment, and construction of phylogenetic trees from representative sequences of OTUs, and through downstream statistical analysis, visualization, and production of publication-quality graphics. QIIME has been applied to studies based on billions of sequences from thousands of samples.
Taxonomic differences identified in this study were confirmed by quantitative polymerase chain reaction (qPCR) and adjusted for false discovery rate. Data from 794,217 16S rRNA gene sequences revealed that CRC case subjects had decreased overall microbial community diversity. In taxonomy-based analyses, lower relative abundance of Clostridia and increased carriage of Fusobacterium and Porphyromonas were found in case subjects compared with control subjects. Clostridia include some bacterial family members that ferment dietary fiber to butyrate, which is a major colonic metabolite that may inhibit inflammation and carcinogenesis in the colon, while Fusobacterium and Porphyromonas are related to inflammation in the mouth and gastrointestinal track.
"Our findings are important because identification of these microbes may open the door for colorectal cancer prevention and treatment," said first author Dr. Jiyoung Ahn, assistant professor of population health at the New York University School of Medicine. "Our next step is to study how diet and lifestyle factors modulate these gut bacteria associated with colorectal cancer. This may lead to ways to prevent this disease."
The paper was published in the December 6, 2013, online edition of the Journal of the [US] National Cancer Institute.
Related Links:
New York University School of Medicine
Roche
QIIME
Latest Molecular Diagnostics News
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
- Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations
- Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer
- Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
- Liquid Biopsy Captures Gene Activity Patterns in Small-Cell Lung Cancer
- Genomic Sequencing Identifies Actionable Findings to Guide Rare Disease Management
- Combined Blood Tests Help Clarify Colorectal Cancer Recurrence Risk
- Blood RNA Test May Detect Precursors to Ovarian Cancer
- Microsatellite Instability Test Gains FDA Approval for Immunotherapy Selection
- Blood-Detected Chromosomal Changes May Refine Colorectal Cancer Risk Assessment
- AI Tool Automates Variant Curation and Interpretation for Cancer Whole-Genome Sequencing
- Portable Test Detects Zika and Hepatitis C RNA from Whole Blood
- DNA Methylation May Predict Treatment Response in Myelodysplastic Syndromes
- Blood-Based Test May Predict Response Across Rheumatoid Arthritis Drug Classes
- New Research Examines Hi-C Sequencing Across Solid Tumors and Lymphoma
Channels
Clinical Chemistry
view channel
Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
Prostate cancer is the second leading cause of cancer-related death among men in the United States, with an estimated 333,830 new cases and 36,320 deaths this year, according to the American Cancer Society.... Read more
Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
Rheumatic heart disease (RHD) causes hundreds of thousands of deaths annually, disproportionately affecting children and young adults in low- and middle-income countries. Early detection remains challenging... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







